Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Protective Immune Cells' Function Altered by Cigarette Smoke Components

Cigarette smoking is prevalent worldwide and causes numerous diseases, yet our understanding of how cigarette smoke (CS) causes serious respiratory illnesses is incomplete, and has held back the development of effective treatments. Researchers headed by a team

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cigarette smoking is prevalent worldwide and causes numerous diseases, yet our understanding of how cigarette smoke (CS) causes serious respiratory illnesses is incomplete, and has held back the development of effective treatments. Researchers headed by a team at Monash University’s Biomedicine Discovery Institute carried out a preclinical study showing how multiple chemicals found in cigarette smoke and in e-cigarettes alter the function of a key type of immune cell found in the lungs.

Their findings suggest that these alterations make cigarette smokers, and those exposed to second- and third-hand smoke, more susceptible to respiratory infections, and worsen smoking-related inflammatory diseases such as chronic obstructive pulmonary disease (COPD).

First author Wael Awad, PhD and colleagues reported their results in Journal of Experimental Medicine, in a paper titled “Cigarette smoke components modulate the MR1-MAIT axis.” The research was co-led by Jamie Rossjohn, PhD, at Monash University’s Biomedicine Discovery Institute, together with Professor David P. Fairlie, PhD, at the Institute for Molecular Bioscience at the University of Queensland, Alexandra J. Corbett, PhD, at the University of Melbourne based at the Peter Doherty Institute for Infection and Immunity, and Philip M. Hansbro, PhD, at the Centenary Institute based at the University of Technology, Sydney.

Cigarette smoking is known to impair the immune system’s response to infections and promote inflammation in the lungs that can lead to or exacerbate COPD, which the authors noted is the third leading cause of chronic morbidity and death worldwide, according to a WHO report. COPD patients are more susceptible to influenza infections that can, in turn, worsen the underlying disease by increasing airway inflammation and promoting the destruction of the lung’s air sacs.

There are currently no effective treatments for COPD. “… the mechanisms that drive the development and progression of CS-induced chronic inflammation and COPD are poorly understood, and this has severely hampered the development of effective treatments,” the researchers noted.

As Awad also pointed out, “until now the mechanisms underlying the skewed immune responses in people exposed to cigarette smoke, and how they are related to smoke-associated diseases like COPD, remain unclear.”

In their study, the researchers looked at the effects of cigarette smoke on mucosal-associated invariant T (MAIT) cells, a type of immune cell found in the lungs and other tissues of the body. MAIT cells help fight off bacterial and viral infections and can promote inflammation or tissue repair. The investigators also stated that, “MAIT cells have recently been reported to be significantly reduced in the peripheral blood of smokers and patients with COPD, yet accumulate in the lungs of COPD patients.”

MAIT cells are activated by an antigen-presenting protein called MR1 that is found in almost every cell of the body. MR1 recognizes chemicals produced by bacteria and presents them at the surface of infected cells in order to activate MAIT cells and initiate an immune response. “MR1 is a ubiquitous molecule that presents bacterial metabolites to MAIT cells, which are highly abundant in the lungs,” the authors further wrote.

Awad commented, “We suspected that some of the more than 20,000 chemicals present in cigarette smoke that smokers inhale might also bind to MR1 and influence the activity of MAIT cells in the lungs.” However, as the authors acknowledged, “Whether CS components can bind MR1, impact MAIT cell functions in the lungs, and how they are related to the pathogenesis of COPD are yet to be elucidated.”

Fairlie added, “While we know that smoke from cigarettes, bushfires, cooking, vehicle exhausts and burning waste pose significant health risks, we still surprisingly know relatively little about how the specific components pf smoke affect our immune system and how they impact multiple parts of the human body.”

As part of their reported study the researchers used computer modeling to predict which components of cigarette smoke might be recognized by MR1. They found that several of these molecules not only bound to the protein but also either increased or decreased its amounts on the surface of cells.

Through their study the investigators confirmed that mice repeatedly exposed to cigarette smoke developed symptoms of lung disease and this was worsened if also infected by influenza. It was also found that long-term exposure to cigarette smoke altered the protection provided to mice by their MAIT cells, making them less able to fight off influenza infections and more prone to the development of COPD disease.

“Chronic CS exposure altered MAIT cell phenotype and function and attenuated MAIT cell responses to influenza A virus infection in vivo,” the team wrote, also noting in their paper, that “COPD patients are highly susceptible to influenza that exacerbates their conditions.”

Hansbro added, “We found that mice lacking MAIT cells were also protected from cigarette smoke–induced COPD, showing reduced levels of lung inflammation and no tissue deterioration in their lung’s air sacs.” In their report the authors in addition stated, “MR1-deficient mice were partially protected from the development of chronic obstructive pulmonary disease (COPD) features that were associated with CS exposure. Thus, CS can impair MAIT cell function by diverse mechanisms, and potentially contributing to infection susceptibility and disease exacerbations.”

Awad concluded, “Overall, our study reveals that components of cigarette smoke can bind to the protein MR1 and reduce the functions of protective immune cells called MAIT cells. This increases susceptibility to infections [and] worsens progression of lung disease.” The researchers now plan to investigate exactly which MAIT cell pathways are impacted by cigarette smoke, to help learn how to better treat COPD and other lung diseases. “This study demonstrates the power of collaboration and the insights we can gain with inter-disciplinary science,” Corbett said.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →